Peptide Guide
Compare Research Areas
A side-by-side look at the three peptides in our research library — what each is, where the science focuses, and how they differ.
How to use this page
Each peptide in our research library has a distinct profile — different origins, different biological pathways under investigation, and different areas of focus. This comparison is designed to help you understand those differences at a glance, not to recommend one option over another. Any decision about whether a peptide may be appropriate for your dog should be made with a licensed veterinarian.
Origin
BPC-157
Laboratory-synthesized peptide based on a sequence associated with a protective compound found in gastric fluid.
TB-500
Synthetic fragment corresponding to the active region of thymosin beta-4, a naturally occurring protein involved in cell movement and tissue repair.
KPV
Tripeptide fragment derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH).
Primary research focus
BPC-157
Tissue repair, tendon and ligament recovery, inflammatory balance, gastrointestinal support.
TB-500
Wound healing, muscle and connective tissue recovery, collagen organization, circulation support.
KPV
Intestinal inflammatory signaling, immune-cell activity, gastrointestinal lining support.
Research stage
BPC-157
Preclinical — laboratory and animal-model studies. No large-scale clinical trials in dogs.
TB-500
Preclinical — laboratory and animal-model studies. TB-500 is not identical to thymosin beta-4 and should not be treated as equivalent.
KPV
Preclinical — primarily in vitro and rodent studies. Canine-specific data is limited.
Administration route
BPC-157
Typically subcutaneous injection or oral; route depends on the condition being addressed.
TB-500
Typically subcutaneous or intramuscular injection.
KPV
Oral or subcutaneous; route and formulation depend on the target area.
Key distinction
BPC-157
Broad tissue-repair profile across multiple systems — musculoskeletal, GI, and circulatory.
TB-500
Focused on post-injury cellular repair and recovery; distinct from BPC-157 despite frequent comparison.
KPV
More narrowly focused on GI and immune pathways compared to BPC-157 and TB-500.
Safety note
BPC-157
Long-term safety in dogs not established. Individual responses vary. Veterinary oversight required.
TB-500
Not FDA-approved. Long-term effects in dogs not established. Requires licensed veterinary prescription.
KPV
Investigational. Canine safety profile not fully characterized. Veterinary guidance essential.
Ready to explore your options?
Our concierge process connects you with a licensed veterinarian who can review your dog's individual needs and discuss whether any of these research areas may be relevant.